Atherotech To Exhibit VAP(R) Cholesterol Test At American Heart Association Scientific Sessions 2008

Atherotech, Inc., a
cardio-diagnostic company, today announced it will be exhibiting its VAP(R)
Cholesterol Test in booth No. 2918 at the American Heart Association
Scientific Sessions 2008. The annual meeting takes place Nov. 8-12 at the
Ernest N. Morial Convention Center in New Orleans.

Atherotech representatives will be available to discuss the VAP
Cholesterol Test during regular exhibit hours on October 9, 10 and 11 in
booth No. 2918, and the VAP Test will be provided via blood draw to
qualified attendees. Test results will be returned via mail after the

The VAP (vertical auto profile) Test is the only commercially available
advanced lipid profile that routinely reports all three lipoprotein
parameters – LDL, non-HDL and apoB – considered necessary by the 2008
expert consensus guidelines issued by the American Diabetes Association and
American College of Cardiology.

“Detailed risk profiling through advanced lipid testing is changing the
way we evaluate and manage heart disease risk,” said Atherotech Chief
Medical Officer James Ehrlich, M.D. “The VAP Test is affordable, widely
covered by insurance and will play an increasingly important role in heart
attack and stroke prevention.”

The VAP Test reports all 15 lipoprotein measurements with a single
test, and unlike other lipid profiles, it directly measures LDL and HDL and
includes Lp(a) and apoB as part of its standard test. Atherotech has
announced plans to add apolipoprotein A-1 (apoA1) to its reporting in early
2009. ApoA1 is the main component of protective HDL cholesterol and studies
have shown that the apoB:apoA1 ratio may correlate better with increased
risk of coronary artery disease (CAD) than total cholesterol and LDL:HDL

People with a family history or an existing condition of diabetes, high
blood pressure or heart disease – or who are already taking
cholesterol-lowering medication – are candidates for the comprehensive VAP

The VAP Cholesterol Test has been shown to identify significantly more
patients with lipid abnormalities than the standard lipid panel
(cholesterol and triglyceride test). Risks of both heart disease and
diabetes can be reduced with the right preventive treatments, which is why
more accurate diagnosis is critical.

About Atherotech, Inc.

Atherotech is a cardio-diagnostic company focusing on direct
measurement of the comprehensive lipid panel using the company’s patented
VAP(R) technology, which directly measures the cholesterol content of all
lipids, components and subclasses. The VAP Test is the first cholesterol
profile to comply with updated National Cholesterol Education Program ATP
III recommendations for LDL measurement and the only commercially available
advanced lipid profile that routinely reports all three lipoprotein
parameters considered necessary by the American Diabetes Association and
American College of Cardiology expert consensus guidelines. The VAP
Cholesterol Test is available through national and regional diagnostic
laboratories and is reimbursed by many of the largest private insurers as
well as Medicare. For more information, visit thevaptest.

Atherotech, Inc.

This entry was posted in Uncategorized. Bookmark the permalink.